Printer Friendly

ZYNAXIS ANNOUNCES PROMOTION OF DR. MUIRHEAD AND RESCHEDULES DIAGNOSTIC PRODUCT CLINICALS

 MALVERN, Pa., Feb. 16 /PRNewswire/ -- Zynaxis, Inc. (NASDAQ: ZNXS) today announced that Dr. Katherine A. Muirhead, Ph.D., has been promoted to the position of senior vice president, research at the company. Dr. Muirhead is a co-founder of Zynaxis and was previously vice president of research. Dr. Muirhead is responsible for the management of all therapeutic research programs including restenosis, radiation synovectomy, oncology and psoriasis.
 Thomas Cekoric, Jr., president and chief executive officer, stated, "Zynaxis is completing the final development phase of its Zymmune(TM) CD4/CD8 cell monitoring system. Currently, CD4/CD8 analysis is performed by a process called flow cytometry. We expect our significantly improved Zymmune monitoring system to be superior to flow cytometry due to several important advantages -- speed, ease of use and lower cost. Due to a change in a raw material component of the assay, we have been delayed in compiling the necessary data for the company's premarket submission to the FDA. However, we are confident that we will be able to compile the necessary data and submit it to the FDA in the spring."
 Zynaxis, Inc. is a biotechnology company engaged in the development of new therapeutic drug delivery systems and advanced cellular diagnostic products.
 -0- 2/16/93
 /CONTACT: Thomas Cekoric, Jr., president and CEO of Zynaxis, 215-889-2200; or Melissa Wilmoth of Cameron Associates, 212-644-9560, for Zynaxis/
 (ZNXS)


CO: Zynaxis, Inc. ST: Pennsylvania IN: MTC SU: PER

LR-TS -- NY101 -- 6838 02/16/93 13:43 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 16, 1993
Words:243
Previous Article:CHEMICAL BANKING CORPORATION DECLARES DIVIDEND
Next Article:OMNICORP AGREES TO MERGE WITH NORTH AMERICAN TIRE RECYCLING LTD.
Topics:


Related Articles
ZYNAXIS REPORTS SECOND QUARTER AND SIX MONTH RESULTS
ZYNAXIS RECEIVES SBIR TO DEVELOP LDL DIAGNOSTIC TEST
WALTER BRANDES JOINS ZYNAXIS AS VICE PRESIDENT OF SALES AND MARKETING
MICHAEL CHRISTIE, PH.D. JOINS ZYNAXIS AS VICE PRESIDENT OF PROCESS DEVELOPMENT
ZYNAXIS REPORTS THIRD QUARTER AND NINE MONTH RESULTS
ZYNAXIS APPOINTS KEITH MANSFORD, PH.D. TO BOARD OF DIRECTORS
PAUL K. HORAN TO CONTINUE AS CHIEF SCIENTIFIC ADVISOR TO ZYNAXIS
ZYNAXIS REPORTS FOURTH QUARTER AND YEAR END RESULTS
ZYNAXIS ANNOUNCES RESIGNATION OF THOMAS CEKORIC, JR.
ZYNAXIS, INC. REPORTS DATA ON IMPROVED OLIGONUCLEOTIDE UPTAKE d at the Keystone Symposium on Drug Delivery that, in tissue culture studies, the...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters